Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11668400 | 0.82 | LCK (0.58) | LCKFYNMAPTCYP1A2LMNA | |
| SCHEMBL134325 | 0.82 | LCK (0.64) | LCKFYNMAPTCYP1A2LMNA | |
| SCHEMBL67742 | 0.82 | CES2 (0.48) | CES2MAPTGAALMNAPOLB | |
| SCHEMBL4728302 | 0.82 | RXRA (0.46) | RXRARXRBRXRGLCKFYN | |
| SCHEMBL5363484 | 0.82 | CA12 (0.48) | CES2RXRARXRBRXRGLCK | |
| SCHEMBL29482054 | 0.82 | CES2 (0.47) | CES2RXRARXRBRXRGLCK | |
| SCHEMBL12097304 | 0.82 | GPBAR1 (0.47) | CES2RXRARXRBRXRGLCK | |
| SCHEMBL21609775 | 0.82 | CES2 (0.47) | CES2RXRARXRBRXRGLCK | |
| SCHEMBL30738524 | 0.82 | GPBAR1 (0.47) | CES2RXRARXRBRXRGLCK | |
| Hydrochloric Acid SCHEMBL6130934 | 0.81 | LCK (0.61) | LCKFYNMAPTCYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| US-7166598-B2 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
| CN-1152877-C | Piperazine derivatives | ����ҩƷ��ҵ��ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| CN-1334812-A | Piperazine derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-02-06 | — | — | CN | disclosed |
| EP-1140924-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035915-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-22 | — | — | WO | disclosed |
| EP-0556674-B1 | 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity | HOECHST AG (DE) | 1996-06-19 | — | — | EP | disclosed |
| US-5373024-A | 3,5-Substituted benzoylguanidines, process for their preparation, their use as a medicament of diagnostic and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-12-13 | — | — | US | disclosed |
| EP-0556674-A1 | 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | disclosed |
| US-4377521-A | ANTILIPEMIC | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4138399-A | Sulfamylbenzoic acid | PFIZER INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4124590-A | CARDIOVASCULAR DISORDERS, ANTILIPEMIC AGENTS | PFIZER INC. (US) | 1978-11-07 | — | — | US | disclosed |
| US-3992441-A | ANTILIPEMIC | PFIZER INC. (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | CES2 3274/4885RXRA 4477/4885RXRB 4200/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | CES2 3220/4885RXRA 4466/4885RXRB 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.